시장보고서
상품코드
1478594

세계의 류마티스 관절염 치료제 시장 규모 : 약물 유형, 투여 경로, 판매 채널, 유통 채널별 - 지역별 전망, 경쟁 전략, 부문 예측(-2033년)

Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

발행일: | 리서치사: SPER Market Research Pvt. Ltd. | 페이지 정보: 영문 234 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 류마티스 관절염 치료제 시장 규모는 2033년까지 3.8%의 연평균 복합 성장률(CAGR)을 나타내고, 787억 1,842만 달러 규모로 성장할 것으로 예상됩니다.

류마티스 관절염은 신체의 면역체계가 관절을 포함한 자신의 조직을 공격하는 자가면역질환입니다. 류마티스 관절염 치료에 사용되는 약물은 항류마티스 약물로 알려져 있습니다. 모든 연령층이 이 질환에 걸릴 수 있지만, 노인이 가장 취약한 것으로 알려져 있습니다. 류마티스 관절염의 증상으로는 관절의 부종, 뻣뻣함, 통증, 불편함 등이 있습니다. 류마티스 관절염은 현재 치료법이 확립되어 있지 않습니다.

2020년 1월 30일, 세계보건기구(WHO)는 코로나19를 세계 공중보건 비상사태로 규정했고, 코로나19는 전 세계 약 210개국에 영향을 미쳤으며, Lancet Rheumatology 2020에 따르면 류마티스 관절염 환자의 코로나19 감염은 심각한 증상을 유발할 수 있다고 합니다. 감염은 심각한 증상으로 이어질 가능성이 높습니다. 하이드록시클로로퀸과 같은 특정 DMARDs는 류마티스 관절염 치료에 자주 사용될 뿐만 아니라 코로나19 치료제로서의 가능성도 연구되고 있습니다.

세계 류마티스 관절염 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 성장 촉진요인 및 억제요인·기회·과제 분석
  • 시장에 대한 COVID-19의 영향

제5장 시장 변수와 전망

  • SWOT 분석
  • PESTEL 분석
  • Porter의 Five Forces 분석
  • 히트맵 분석

제6장 경쟁 구도

  • 제조거점 분포·판매 지역·제품 유형
  • 인수합병(M&A)·제휴·제품 발매·협력

제7장 세계의 류마티스 관절염 치료제 시장 : 약제 클래스별

  • 세계 시장 규모·점유율·예측
  • 질환 조절성 항류머티즘제(DMARD)
  • 비스테로이드성 항염증제(NSAID)
  • 코르티코스테로이드
  • 요산약
  • 기타

제8장 세계의 류마티스 관절염 치료제 시장 : 투여 경로별

  • 세계 시장 규모·점유율·예측
  • 경구
  • 비경구

제9장 세계의 류마티스 관절염 치료제 시장 : 판매채널별

  • 세계 시장 규모·점유율·예측
  • 처방약
  • OTC 의약품

제10장 세계의 류마티스 관절염 치료제 시장 : 유통 채널별

  • 세계 시장 규모·점유율·예측
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제11장 세계의 류마티스 관절염 치료제 시장 예측

  • 시장 규모·시장 점유율

제12장 세계의 류마티스 관절염 치료제 시장 : 지역별

  • 시장 규모·시장 점유율 추이·예측
  • 아시아태평양
  • 유럽
  • 중동 및 아프리카
  • 북미
  • 라틴아메리카

제13장 기업 개요

  • AbbVie Inc.
  • Johnson & Johnson Innovative Medicine
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • 기타

제14장 약어 리스트

제15장 참고 링크

제16장 결론

제17장 조사 범위

LSH 24.05.22

Rheumatoid Arthritis Drugs Market Introduction and Overview

According to SPER market research, Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033 state that the Global Rheumatoid Arthritis Drugs Market is predicted to reach 78718.42 million by 2033 with a CAGR of 3.8%.

Rheumatoid arthritis is an autoimmune disease that results in the body's immune system attacking its own tissues, including joints. This leads to edema and painful joint stiffness. A medication used to treat rheumatoid arthritis is known as an anti-rheumatic medication. All ages are affected by this ailment, albeit the elderly are most susceptible to it. Rheumatoid arthritis symptoms include swelling, stiffness, pain, and discomfort in the joints. Rheumatoid arthritis currently has no recognized treatment.

On January 30, 2020, the World Health Organization (WHO) deemed the COVID-19 pandemic a global public health emergency. Globally, COVID-19 has had an impact on around 210 countries. Patients with rheumatoid arthritis who also have COVID-19 infection may be more likely to experience severe symptoms and other problems, according to the Lancet Rheumatology 2020. Certain DMARDs, such hydroxychloroquine, are being studied as possible COVID-19 therapies in addition to being often used to treat rheumatoid arthritis.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Rheumatoid Arthritis Drugs Market Segmentation

By Drug Class Type: Based on the Drug Class Type, Global Rheumatoid Arthritis Drugs Market is segmented as, Disease-modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others.

By Route of Administration: Based on the Route of Administration, Global Rheumatoid Arthritis Drugs Market is segmented as; Oral, Parenteral.

By Sales Channel: Based on the Sales Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Prescription-based Drugs, Over-the-counter Drugs.

By Distribution Channel: Based on the Distribution Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Rheumatoid Arthritis Drugs Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Rheumatoid Arthritis Drugs Market Manufacturing Base Distribution, Sales Area, Ingredients
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Rheumatoid Arthritis Drugs Market

7. Global Rheumatoid Arthritis Drugs Market, By Drug Class Type (USD Million) 2020-2033

  • 7.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2020-2026
  • 7.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2027-2033
  • 7.3. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • 7.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.5. Corticosteroids
  • 7.6. Uric Acid Drugs
  • 7.7. Others

8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration (USD Million) 2020-2033

  • 8.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2020-2026
  • 8.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2027-2033
  • 8.3. Oral
  • 8.4. Parenteral

9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel (USD Million) 2020-2033

  • 9.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2020-2026
  • 9.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2027-2033
  • 9.3. Prescription-based Drugs
  • 9.4. Over-the-counter Drugs

10. Global Rheumatoid Arthritis Drugs Market, By Distribution Channel (USD Million) 2020-2033

  • 10.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2020-2026
  • 10.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2027-2033
  • 10.3. Hospital Pharmacy
  • 10.4. Retail Pharmacy
  • 10.5. Online Pharmacy

11. Global Rheumatoid Arthritis Drugs Market, Forecast, 2020-2033 (USD Million)

  • 11.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share

12. Global Rheumatoid Arthritis Drugs Market, By Region, 2020-2033 (USD Million)

  • 12.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2020-2026)
  • 12.2. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2027-2033)
  • 12.3. Asia-Pacific
    • 12.3.1. Australia
    • 12.3.2. China
    • 12.3.3. India
    • 12.3.4. Japan
    • 12.3.5. South Korea
    • 12.3.6. Rest of Asia-Pacific
  • 12.4. Europe
    • 12.4.1. France
    • 12.4.2. Germany
    • 12.4.3. Italy
    • 12.4.4. Spain
    • 12.4.5. United Kingdom
    • 12.4.6. Rest of Europe
  • 12.5. Middle East and Africa
    • 12.5.1. Kingdom of Saudi Arabia
    • 12.5.2. United Arab Emirates
    • 12.5.3. Qatar
    • 12.5.4. South Africa
    • 12.5.5. Egypt
    • 12.5.6. Morocco
    • 12.5.7. Nigeria
    • 12.5.8. Rest of Middle-East and Africa
  • 12.6. North America
    • 12.6.1. Canada
    • 12.6.2. Mexico
    • 12.6.3. United States
  • 12.7. Latin America
    • 12.7.1. Argentina
    • 12.7.2. Brazil
    • 12.7.3. Rest of Latin America

13. Company Profile

  • 13.1. AbbVie Inc.
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Johnson & Johnson Innovative Medicine
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Amgen Inc.
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. Pfizer Inc.
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. Novartis AG
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. Sanofi S.A.
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. F. Hoffmann-La Roche Ltd.
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Merck & Co., Inc.
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. Bristol-Myers Squibb Company
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Eli Lilly and Company
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Others

14. List of Abbreviations

15. Reference Links

16. Conclusion

17. Research Scope

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제